1. To retrospectively determine the frequency and characteristics of abnormalities suspicious for lung cancer on the last CT screen of NLST participants who had lung cancer diagnosed within a year of a negative screen

2. To determine whether each interval cancer had been overlooked on the CT (false negative) or was new or undetectable on the CT (interval cancer)

3. To assess the clinical outcomes of false negative and interval lung cancers in terms of stage, treatment, and mortality

Denise Aberle, MD UCLA
William Black, MD Dartmouth University
Fenhai Duan, PhD Brown University
Kavita Garg, MD University of Colorado
Eric Hart, MD Northwestern University
Subi Inampudi, MD Abbott Northwestern Hospital
Ella Kazerooni, MD University of Michigan
Paul Kvale, MD Henry Ford Hospital
Hrudaya Nath, MD University of Alabama
Paul Pinsky, PhD National Cancer Institute
Jubal Watts, MD University of Alabama
Carl Zylak, MD